ArticleBMC health services research2026
Operational performance of GeneXpert for tuberculosis diagnosis in West Java province, Indonesia: a public health evaluation.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeted next-generation sequencing for direct drug-resistant tuberculosis detection in sputum samples in Indonesia: an implementation study (2024-25).The Lancet regional health. Southeast Asia · 2026Article
- Pretreatment out-of-pocket costs for people with drug-resistant tuberculosis in Bandung, Indonesia.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundGeneXpert is instrumental in tuberculosis diagnosis. Operational challenges are widely reported, but comprehensive evaluations of its operational performance are rare.
methodsWe conducted a health facility survey in 40 community health centres with GeneXpert machines in West Java, Indonesia, and interviewed nurses, laboratory technicians, and program officers. We developed indicators and data collection tools using the World Health Organization GeneXpert implementation manual and Consolidated Framework for Implementation Research.
resultsGeneXpert has been implemented across the system with variable success. Several indicators were scored relatively low, which included facilities with Xpert-trained nurses (42%), samples referred from private providers (2%), samples transported in ≤ 1 day (61%), facilities with annual test volumes ≥ 3000 (16%), error rates ≤ 3% (46%), no result rates ≤ 1% (66%), absence of cartridge stockouts (72%) or machine module failure (37%), and annual machine calibration (58%). Barriers spanned multiple domains and layers. At Community Health Centres (CHCs), these included understaffing, geographical constraints, and digital infrastructure. Good communication shared at the stakeholders level and pre-assessments prior to GeneXpert deployment were identified as facilitators to GeneXpert utilisation.
conclusionThe Indonesian TB program has made significant progress in GeneXpert implementation. However, improving GeneXpert utilisation requires multisectoral solutions and underscores the need to address real-world constraints in the design and implementation of new TB diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.